Retrospective cohort analysis reveals treatment response and ESKD risk factors in adults with focal segmental glomerulosclerosis, highlighting the need for new therapies.
Key Points
Around 55% of patients with focal segmental glomerulosclerosis achieved remission with immunosuppressive therapy, but relapse rates were notably high.
Non-responders had a significantly increased risk of progressing to end-stage kidney disease compared to responders, with a sHR of 2.22.
The study evaluated treatment response and outcomes in a diverse group of patients over a median follow-up of four years, emphasizing the need for novel therapies.
Baseline eGFR of less than 30 mL/min/1.73m² was found to strongly predict the risk of end-stage kidney disease among patients.